The European Reference Network for Rare Kidney Diseases (ERKNet, hereinafter called “the Network”) is an organization authorized by the European Commission to promote healthcare for rare renal diseases in the European Union. Tasks of the Network include the development and implementation of clinical guidelines and recommendations, clinical pathways and decision-making tools, and the facilitation of research and clinical trials aimed at identifying and testing novel therapies for rare kidney diseases.
A conflict of interest is a set of circumstances that creates a risk that professional judgement or actions regarding a primary interest of the science or the patient will be unduly influenced by a secondary interest. Conflict of interest may distort the interpretation of results and evidence, the analysis of data, and the development of research methods.
The Network adheres to ethical criteria, is transparent, and avoids any conflict of interest when developing and implementing clinical guidelines and recommendations, patient pathways, and clinical decision making tools.
The Network will engage with industry in research and clinical trial programs where appropriate and in an open and transparent manner.
Any new member representative shall be given this policy at the time of their membership approval. The policy will be reviewed regularly by the Network Board.
We understand that the purposes of this policy are to protect the integrity of the Network and its decision-making process as well as to enable our Members and stake holders to have confidence in the integrity, intentions and actions of the Network officers and Board members. To that end, we understand that this policy is not meant to supplement good judgment and all constituents should respect its spirit as well as its wording.